|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...4748495051525354555657...6768» |
- Trial termination: Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle (clinicaltrials.gov) - May 2, 2013
P=N/A, N=20, Terminated, Sponsor: The University of Texas Health Science Center, Houston
Recruiting --> Terminated; Insufficient enrollment
- Enrollment change: Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle (clinicaltrials.gov) - May 2, 2013
P=N/A, N=20, Terminated, Sponsor: The University of Texas Health Science Center, Houston
Recruiting --> Terminated; Insufficient enrollment N=40 --> 20
- ||| Mozobil (plerixafor) / Sanofi
Enrollment closed: Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor (clinicaltrials.gov) - May 2, 2013
P4, N=9500, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
N=40 --> 20 Enrolling by invitation --> Active, not recruiting
- | New P1/2 trial: Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain (clinicaltrials.gov) - May 1, 2013
P1/2, N=52, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- lansoprazole / Generic mfg., clarithromycin / Generic mfg., amoxicillin / Generic mfg.
Trial completion: Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura (clinicaltrials.gov) - Apr 30, 2013
P4, N=26, Completed, Sponsor: Mahidol University
Enrolling by invitation --> Active, not recruiting Recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Enrollment closed: Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Apr 30, 2013
P1/2, N=180, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Trial completion: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 30, 2013
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Completed
- pegylated liposomal doxorubicin / Generic mfg., lenalidomide / Generic mfg.
Trial completion: Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) (clinicaltrials.gov) - Apr 29, 2013
P2, N=57, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed Active, not recruiting --> Completed
- | ATryn (antithrombin) / LFB Biotechnologies, Knight Therap
Trial suspension, Surgery: Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery (clinicaltrials.gov) - Apr 28, 2013
P4, N=60, Suspended, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Enrolling by invitation --> Suspended
- Acoalan (antithrombin gamma) / Kyowa Hakko Kirin
Trial termination: A Phase 3 Clinical Study of KW-3357 in Patients With DIC (clinicaltrials.gov) - Apr 23, 2013
P3, N=10, Terminated, Sponsor: Kyowa Hakko Kirin Company, Limited
Enrolling by invitation --> Suspended Recruiting --> Terminated
- | Xyntha (moroctocog alfa) / Pfizer
Trial termination: Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings (clinicaltrials.gov) - Apr 23, 2013
P4, N=224, Terminated, Sponsor: Pfizer
Recruiting --> Terminated Recruiting --> Terminated; See termination reason in detailed description.
- Xyntha (moroctocog alfa) / Pfizer
Enrollment change: Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings (clinicaltrials.gov) - Apr 23, 2013
P4, N=224, Terminated, Sponsor: Pfizer
Recruiting --> Terminated; See termination reason in detailed description. N=300 --> 224
- Acoalan (antithrombin gamma) / Kyowa Hakko Kirin
Trial completion: A Clinical Study of KW-3357 in Patients With DIC (clinicaltrials.gov) - Apr 23, 2013
P3, N=10, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
N=300 --> 224 Recruiting --> Completed
- | New P2 trial: Control of Major Bleeding After Trauma Study (clinicaltrials.gov) - Apr 22, 2013
P2, N=150, Not yet recruiting, Sponsor: Denver Health and Hospital Authority
- Rituxan (rituximab) / Roche
Trial termination: Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 22, 2013
P2, N=3, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Completed --> Terminated; Lack of Accrual
- Rituxan (rituximab) / Roche
Enrollment change: Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 22, 2013
P2, N=3, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Completed --> Terminated; Lack of Accrual N=41 --> 3
- Trial completion: Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma (clinicaltrials.gov) - Apr 22, 2013
P2, N=46, Completed, Sponsor: Roswell Park Cancer Institute
N=41 --> 3 Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 21, 2013
P1, N=6, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed N=17 --> 6
- lorvotuzumab mertansine (IMGN901) / AbbVie
Enrollment change: IMGN901: BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 21, 2013
P1, N=37, Completed, Sponsor: ImmunoGen, Inc.
N=17 --> 6 N=80 --> 37
- Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment open: Ruxolitinib Prior to Transplant in Patients With Myelofibrosis (clinicaltrials.gov) - Apr 21, 2013
P2, N=86, Recruiting, Sponsor: John Mascarenhas
N=80 --> 37 Not yet recruiting --> Recruiting
- melphalan / Generic mfg., lenalidomide / Generic mfg.
Enrollment closed: Lenalidomide and High-Dose Melphalan (clinicaltrials.gov) - Apr 18, 2013
P1/2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | NovoEight (turoctocog alfa) / Novo Nordisk
Enrollment closed: Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 (clinicaltrials.gov) - Apr 17, 2013
P3, N=214, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- | luminespib (AUY922) / Ligand
Enrollment open: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Apr 17, 2013
P2, N=25, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Enrolling by invitation --> Active, not recruiting Suspended --> Recruiting
- ||| thalidomide / Generic mfg.
Trial completion: Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide. (clinicaltrials.gov) - Apr 16, 2013
P=N/A, N=529, Completed, Sponsor: LEO Pharma
Suspended --> Recruiting Active, not recruiting --> Completed
- Amplimexon (imexon) / Amplimed Corp
Enrollment closed: Imexon for Relapsed Follicular and Aggressive Lymphomas (clinicaltrials.gov) - Apr 16, 2013
P2, N=18, Active, not recruiting, Sponsor: University of Rochester
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Ojjaara (momelotinib) / GSK
Trial completion: Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) (clinicaltrials.gov) - Apr 16, 2013
P1/2, N=166, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial withdrawal: PLEX-RCT: The Plasma Large-Volume Exchange RCT (clinicaltrials.gov) - Apr 15, 2013
P3, N=0, Withdrawn, Sponsor: London Health Sciences Centre
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: PLEX-RCT: The Plasma Large-Volume Exchange RCT (clinicaltrials.gov) - Apr 15, 2013
P3, N=0, Withdrawn, Sponsor: London Health Sciences Centre
Not yet recruiting --> Withdrawn N=150 --> 0
- Trial termination: Studying Fentanyl in Patients With Cancer (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=2, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=150 --> 0 Recruiting --> Terminated; poor accrual
- Enrollment change: Studying Fentanyl in Patients With Cancer (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=2, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Terminated; poor accrual N=20 --> 2
- ||||||| Kovaltry (octocog alfa) / Bayer, CSL Behring
Trial completion: Leopold I: Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A (clinicaltrials.gov) - Apr 15, 2013
P3, N=74, Completed, Sponsor: Bayer
N=20 --> 2 Active, not recruiting --> Completed
- || BeneFix (nonacog alfa) / Pfizer
P4 data, Enrollment change: Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B (clinicaltrials.gov) - Apr 10, 2013
P=N/A, N=183, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed N=11 --> 183
- NovoSeven (eptacog alfa) / Novo Nordisk
Surgery: A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors (clinicaltrials.gov) - Apr 10, 2013
P=N/A, N=15, Completed, Sponsor: Novo Nordisk A/S
- | NovoEight (turoctocog alfa) / Novo Nordisk
Trial completion: Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A (clinicaltrials.gov) - Apr 10, 2013
P1, N=15, Completed, Sponsor: Novo Nordisk
N=11 --> 183 Active, not recruiting --> Completed
- | lenalidomide / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (clinicaltrials.gov) - Apr 9, 2013
P2, N=35, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | MRX34 / Synlogic
New P1 trial: A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (clinicaltrials.gov) - Apr 9, 2013
P1, N=48, Recruiting, Sponsor: Mirna Therapeutics, Inc.
- |||||| Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Enrollment open: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia (clinicaltrials.gov) - Apr 9, 2013
P3, N=95, Recruiting, Sponsor: Octapharma
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| carfilzomib / Generic mfg.
P1/2 data: Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma (clinicaltrials.gov) - Apr 9, 2013
P1/2, N=235, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy: Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (clinicaltrials.gov) - Apr 9, 2013
P1, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Trial completion: Acupuncture for Chemo-Induced Peripheral Neuropathy (clinicaltrials.gov) - Apr 8, 2013
P2, N=27, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Trial completion, IO biomarker: MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (clinicaltrials.gov) - Apr 7, 2013
P1/2, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Terminated --> Completed
- | Rebinyn (nonacog beta pegol) / Novo Nordisk
Trial completion: Paradigm-2: Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients (clinicaltrials.gov) - Apr 4, 2013
P3, N=74, Completed, Sponsor: Novo Nordisk A/S
Terminated --> Completed Active, not recruiting --> Completed
- P2 data: Phase II Study of Simvastatin for Relapsed/Refractory Myeloma (clinicaltrials.gov) - Apr 4, 2013
P2, N=0, Withdrawn, Sponsor: James Graham Brown Cancer Center
Active, not recruiting --> Completed Recruiting --> Withdrawn
- P2 data: Phase II Study of Simvastatin for Relapsed/Refractory Myeloma (clinicaltrials.gov) - Apr 4, 2013
P2, N=0, Withdrawn, Sponsor: James Graham Brown Cancer Center
Recruiting --> Withdrawn N=55 --> 0
- || Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Enrollment closed: Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE (clinicaltrials.gov) - Apr 4, 2013
P=N/A, N=105, Active, not recruiting, Sponsor: Bayer
N=55 --> 0 Recruiting --> Active, not recruiting
- melphalan / Generic mfg.
Trial withdrawal: Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- melphalan / Generic mfg.
Enrollment change: Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Withdrawn N=25 --> 0
- ||| Promune (agatolimod) / Pfizer, Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment closed: Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 1, 2013
P1/2, N=63, Active, not recruiting, Sponsor: Mayo Clinic
N=25 --> 0 Completed --> Active, not recruiting
- | BeneFix (nonacog alfa) / Pfizer
Enrollment closed: Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B (clinicaltrials.gov) - Mar 31, 2013
P3, N=24, Active, not recruiting, Sponsor: Pfizer
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
Enrollment closed: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (clinicaltrials.gov) - Mar 28, 2013
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting